Esomeprazole Magnesium Capsule, Delayed Release
Product Images NDC 45865-163

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Esomeprazole Magnesium (NDC 45865-163). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Medsource Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

161 (45865 161)

Label for Esomeprazole Magnesium delayed-release capsules 20 mg, generic for Nexium, packaged by Medsource Pharmaceuticals. The label states the manufacturer as Dr. Reddy's Labs Ltd., India. It includes capsule description, NDC 45865-0163-60, lot and expiration fields, and dosage instructions blank to fill. The package contains 60 capsules.*

FDA Label Image

Figure1 (Figure1)

Chemical structure diagram of esomeprazole magnesium, showing the molecular configuration including two esomeprazole units complexed with magnesium ion and three water molecules (Mg2+·3H2O).*

FDA Label Image

Figure2 (Figure2)

Line graph depicting the percentage maintained over a 6-month period for Esomeprazole Magnesium at 40 mg, 20 mg, and 10 mg doses compared to placebo. The x-axis shows months 0 to 6, and the y-axis indicates percent maintained from 0 to 100. The graph illustrates higher maintenance for 40 mg and 20 mg doses versus 10 mg and placebo groups.*

FDA Label Image

Figure3 (Figure3)

A line graph showing the percent maintained over a period of 6 months for Esomeprazole in different doses (10 mg, 20 mg, 40 mg) compared to placebo. The y-axis represents percent maintained, and the x-axis shows the months from 0 to 6. Lines indicate trends of maintenance rates for each group.*

FDA Label Image

Figure4 (Figure4)

A line graph depicting the percent of patients who are symptom-free over a 28-day diary period. The graph compares three groups: Esomeprazole 40 mg, Esomeprazole 20 mg, and Placebo. The x-axis represents diary days from 0 to 28, and the y-axis represents the percent of symptom-free patients, ranging from 0 to 100%.*

FDA Label Image

Figure5 (Figure5)

A line graph showing the percent of patients symptom-free over a 28-day diary period for three groups: Esomeprazole 40 mg, Esomeprazole 20 mg, and placebo. The graph illustrates increasing percentages of symptom-free patients over time, with Esomeprazole 40 mg showing the highest percentage, followed by Esomeprazole 20 mg, and placebo the lowest.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.